Framing the strategic R&D paradigm shift in Big Pharma: a content analysis of pharmaceutical annual reports

IF 3.1 Q1 COMMUNICATION Journal of Communication Management Pub Date : 2022-04-05 DOI:10.1108/jcom-05-2021-0052
Mary E. Schramm, Katie R. Place, A. Laskin
{"title":"Framing the strategic R&D paradigm shift in Big Pharma: a content analysis of pharmaceutical annual reports","authors":"Mary E. Schramm, Katie R. Place, A. Laskin","doi":"10.1108/jcom-05-2021-0052","DOIUrl":null,"url":null,"abstract":"PurposeBetween 1985 and 2000, the six largest US pharmaceutical firms entered a very active period of partnerships with other pharmaceutical firms to expand their knowledge of biotechnology-based research and development (R&D) frameworks and to bolster the growth of their drug portfolios. The purpose of this study is to examine the annual reports published by these companies for evidence of strategic framing of these partnerships.Design/methodology/approachA content analysis method was most appropriate for this study, as it allows for analysis of a large amount of information and accurate analysis over time. Ninety-six annual reports from the six major US pharmaceutical firms (Abbott, Bristol Myers Squibb, Eli Lilly, Johnson and Johnson, Merck, and Pfizer) were coded. The final codebook included 18 categories derived from framing theory. After collection, the data were uploaded to SPSS for statistical analysis.FindingsResults indicate that mention of partnerships grew considerably in depth and length over time, but companies did not consistently employ frames to describe why or how they engaged in external partnerships.Originality/valueThis is the first study to assess mentions of pharmaceutical firms' external efforts to build their R&D programs and drug portfolios, from the intersecting perspectives of framing theory and the resource-based view (RBV) of the firm, to illustrate how changes were communicated to shareholders during a dynamic period of change within the industry.","PeriodicalId":51660,"journal":{"name":"Journal of Communication Management","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2022-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Communication Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1108/jcom-05-2021-0052","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"COMMUNICATION","Score":null,"Total":0}
引用次数: 0

Abstract

PurposeBetween 1985 and 2000, the six largest US pharmaceutical firms entered a very active period of partnerships with other pharmaceutical firms to expand their knowledge of biotechnology-based research and development (R&D) frameworks and to bolster the growth of their drug portfolios. The purpose of this study is to examine the annual reports published by these companies for evidence of strategic framing of these partnerships.Design/methodology/approachA content analysis method was most appropriate for this study, as it allows for analysis of a large amount of information and accurate analysis over time. Ninety-six annual reports from the six major US pharmaceutical firms (Abbott, Bristol Myers Squibb, Eli Lilly, Johnson and Johnson, Merck, and Pfizer) were coded. The final codebook included 18 categories derived from framing theory. After collection, the data were uploaded to SPSS for statistical analysis.FindingsResults indicate that mention of partnerships grew considerably in depth and length over time, but companies did not consistently employ frames to describe why or how they engaged in external partnerships.Originality/valueThis is the first study to assess mentions of pharmaceutical firms' external efforts to build their R&D programs and drug portfolios, from the intersecting perspectives of framing theory and the resource-based view (RBV) of the firm, to illustrate how changes were communicated to shareholders during a dynamic period of change within the industry.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
构建大型制药公司的战略研发范式转变:制药公司年度报告的内容分析
1985年至2000年间,美国六大制药公司与其他制药公司进入了一个非常活跃的合作时期,以扩大他们在基于生物技术的研发框架方面的知识,并支持其药物组合的增长。本研究的目的是研究这些公司发布的年度报告,以证明这些合作伙伴关系的战略框架。设计/方法/方法内容分析方法最适合于本研究,因为它允许分析大量信息并随着时间的推移进行准确分析。美国六大制药公司(雅培、百时美施贵宝、礼来、强生、默克和辉瑞)的96份年度报告被编码。最终的密码本包括18个类别,这些类别来自框架理论。收集完成后,将数据上传到SPSS进行统计分析。研究结果表明,随着时间的推移,对合作伙伴关系的提及在深度和长度上都有很大的增长,但公司并没有始终如一地使用框架来描述他们为什么或如何参与外部合作伙伴关系。原创性/价值这是第一个从框架理论和公司资源基础观点(RBV)的交叉视角评估制药公司建立其研发计划和药物组合的外部努力的研究,以说明在行业动态变化时期,变化是如何传达给股东的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.40
自引率
6.50%
发文量
29
期刊最新文献
Subjective well-being perceptions of Portuguese Public Relations practitioners: a gender and stages of life analysis Loneliness, office space arrangement and mental well-being of Gen Z PR professionals. Falling into the trap of an agile office? The influence of leaders’ motivational language on employee well-being through relatedness in remote work environments Subjective well-being of public relations and communication professionals in the context of perceived organisational support Understanding subjective well-being across a multi-generational workforce in public relations: a qualitative study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1